Saniona AB (SANION) AI Stock Analysis

• Market Cap: kr2.04B
• Dividend Yield: N/A
• Average Volume (3M): 1.00M
• Price to Earnings (P/E): 7.6
• Beta (1Y): -0.78
• Revenue Growth: 1265.46%
• EPS Growth: N/A
• Country: SE
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.17
• Shares Outstanding: 138,030,140
• 10 Day Avg. Volume: 999,882
• 30 Day Avg. Volume: 1,001,299
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 70 Outperform
• Price Target: kr15.50 ▲(2.92% Upside)

Saniona AB's strong financial performance and undervaluation are the primary drivers of its stock score. While technical indicators show bullish momentum, caution is advised due to overbought signals. The absence of earnings call data and corporate events does not impact the score.

Saniona AB Business Overview & Revenue Model

Company Description

Saniona AB is a biotechnology company focused on developing innovative treatments for rare diseases and neurological disorders. Based in Sweden, the company leverages its proprietary platform to discover and develop novel drug candidates, primarily targeting ion channels and receptors involved in various neurological and metabolic conditions. Saniona's core products are in different stages of clinical development, aimed at addressing significant unmet medical needs in areas such as obesity and pain management.

How the Company Makes Money

Saniona AB generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its drug candidates in exchange for milestone payments and royalties on future sales. Additionally, the company may receive upfront payments as part of licensing agreements for its proprietary technologies and products. As Saniona progresses its candidates through clinical trials, it can also attract further investments and grants aimed at supporting its research and development efforts, contributing to its overall earnings potential.

Saniona AB Financial Statement Overview

Summary

Saniona AB has demonstrated a solid financial recovery with significant improvements in revenue growth, profitability, and cash flow. The company has transitioned from losses to profitability, with a strong balance sheet and cash flow position, reducing financial risk and supporting future growth.

Income Statement

Saniona AB has demonstrated impressive revenue growth, increasing from SEK 16.84M in 2023 to SEK 334.67M in 2024, showcasing a strong market traction in the biotechnology space. The gross profit margin improved significantly to 98.5% in 2024 from 69.9% in 2023, reflecting efficient cost management. Additionally, the net profit margin turned positive to 56.4% in 2024, indicating profitability after years of losses. However, the EBIT and EBITDA margins are high at 72.3% and 76.1%, respectively, showing robust operating performance.

Balance Sheet

The company's balance sheet shows strong financial stability, with a positive shift in stockholders' equity from negative SEK 21.94M in 2023 to positive SEK 231.82M in 2024. The debt-to-equity ratio decreased significantly to 0.05, underscoring a low leverage position which reduces financial risk. The equity ratio improved to 68.2%, highlighting a solid capital structure. This healthy financial position suggests reduced risk and potential for future growth.

Cash Flow

Saniona AB's cash flow statements reflect a remarkable turnaround. The free cash flow increased from negative SEK 85.66M in 2023 to positive SEK 249.07M in 2024, signaling strong cash generation capabilities. The operating cash flow to net income ratio is 1.32, indicating efficient cash management in relation to profits. Moreover, the free cash flow to net income ratio is 1.32, suggesting a healthy conversion of earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	339.70M	334.67M	16.84M	15.28M	10.48M	8.20M
Gross Profit	334.48M	329.58M	11.78M	10.81M	5.85M	4.95M
EBITDA	276.93M	251.90M	-68.28M	-196.00M	-398.86M	-64.64M
Net Income	214.40M	188.71M	-95.81M	-245.36M	-410.90M	-73.43M
Balance Sheet
Total Assets	421.75M	339.73M	64.14M	153.70M	440.25M	692.18M
Cash, Cash Equivalents and Short-Term Investments	308.24M	303.26M	30.96M	111.71M	356.86M	573.87M
Total Debt	6.41M	10.50M	71.41M	81.52M	99.77M	47.51M
Total Liabilities	65.41M	107.92M	86.08M	100.99M	158.25M	88.72M
Stockholders Equity	356.34M	231.82M	-21.94M	52.71M	282.00M	603.46M
Cash Flow
Free Cash Flow	183.62M	249.07M	-85.66M	-282.52M	-346.52M	-179.71M
Operating Cash Flow	256.47M	249.20M	-85.53M	-281.54M	-345.04M	-174.71M
Investing Cash Flow	-72.86M	-124.00K	-129.00K	6.84M	43.16M	99.51M
Financing Cash Flow	75.20M	23.25M	-7.97M	-20.52M	50.60M	621.18M

Saniona AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SANION, the sentiment is Positive. The current price of 15.06 is above the 20-day moving average (MA) of 13.99, above the 50-day MA of 12.96, and above the 200-day MA of 9.35, indicating a bullish trend. The MACD of 0.85 indicates Negative momentum. The RSI at 67.57 is Neutral, neither overbought nor oversold. The STOCH value of 55.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SANION.

Saniona AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	―	kr2.04B	7.61	114.45%	―	1265.46%	―
ONCO	―	kr1.44B	―	―	―	138.11%	31.65%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SYNACT	―	€1.16B	―	-58.41%	―	―	57.54%
XSPRAY	―	€1.09B	―	-41.54%	―	―	0.57%
XBRANE	―	€309.08M	2.32	-16.90%	―	4.64%	―
CANTA	―	kr592.94M	―	-275.87%	―	―	38.99%

Saniona AB Corporate Events

Saniona Selects SAN2668 for Pediatric Epilepsy Clinical Trials

Saniona has announced the selection of SAN2668 as a first-in-class clinical candidate for pediatric epilepsy, showcasing its potential to address significant unmet needs in children with difficult-to-treat epilepsy syndromes. SAN2668 has demonstrated strong efficacy and improved tolerability in preclinical models, positioning it to advance towards early proof-of-concept studies. This development reflects Saniona’s strategy to provide transformative medicines for rare epilepsies, aiming to overcome challenges associated with current treatments.

The most recent analyst rating on (SE:SANION) stock is a Hold with a SEK15.50 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.

Saniona AB Reports Strategic Growth with Key Partnerships and Licensing Agreement

Saniona AB has reported significant progress in its growth phase, highlighted by two major partnerships within a year and a solid financial position. The recent licensing agreement with Jazz Pharmaceuticals for SAN2355 in epilepsy, with an upfront payment of USD 42.5 million, underscores the company’s strategic direction and strengthens its ability to advance its internal programs independently. This development is expected to enhance Saniona’s industry positioning and create long-term value for shareholders.

The most recent analyst rating on (SE:SANION) stock is a Hold with a SEK15.50 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.

Saniona to Host Q2 Investor Call for Strategic Update

Saniona AB announced it will host a Q2 investor call on August 28, 2025, to present results and provide a company update. This event is significant as it offers stakeholders insights into the company’s progress and strategic direction, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (SE:SANION) stock is a Buy with a SEK13.00 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.

Saniona and Jazz Pharmaceuticals Ink Licensing Deal for Epilepsy Treatment

Saniona has entered an exclusive licensing agreement with Jazz Pharmaceuticals for the global development and commercialization of SAN2355, a preclinical asset targeting epilepsy. Saniona will receive $42.5 million upfront, with potential milestone payments and royalties, while Jazz will lead the development and commercialization efforts, enhancing its neuroscience pipeline.

The most recent analyst rating on (SE:SANION) stock is a Hold with a SEK9.00 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.

Saniona to Participate in Key Conferences in Late 2025

Saniona announced its participation in several investor and partnering conferences in the latter half of 2025, showcasing its programs and strategy. This engagement highlights Saniona’s proactive approach in strengthening its industry presence and fostering collaborations, potentially impacting its market positioning and stakeholder relations positively.